Shots:
- Sun Pharma has reported topline data from P-III (INSPIRE-1 & INSPIRE-2) trials assessing Ilumya (100mg) in pts with active psoriatic arthritis (PsA)
- INSPIRE-1 & INSPIRE-2 trials to evaluateIlumya (Q12W) vs PBO in ~800 active PsA pts over 52wks., where INSPIRE-1 enrolled pts with prior anti-TNF exposure & INSPIRE-2 enrolled anti-TNF naïve pts
- Both trials met their 1EPs, with more pts achieving ACR20, plus showed improved PsA signs & symptoms at Wk. 24; Data will support potential FDA submission & shared at a future conference as well as published in a medical journal
Ref: Sun Pharma | Image: Sun Pharma| Press Release
Related News:- Sun Pharma Launches Leqselvi (Deuruxolitinib) to Treat Severe Alopecia Areata in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
